Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 71335-1819

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-1819). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351819)

This text provides information about a medication called Rizatriptan Benzoate 10mg, in a white round F25 tablet form, and it is recommended to store it at room temperature. The medication is a generic equivalent of Maxalt. The packaging is a blister pack containing 10 tablets. The manufacturer is Aurobindo Pharma Limited. Additionally, it warns to keep all drugs out of the reach of children. The expiration date is specified as "EXP MM/YY". The NDC number is 7133518191 08256101523487.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

This description provides an estimate of the probability of achieving an initial headache response within two hours in pooled studies 1, 2, 3, and 4. The figure shows the Kaplan-Meier plot illustrating the likelihood over time of attaining a headache response (no or mild pain) after receiving treatment with rizatriptan benzoate or placebo. The data is based on four placebo-controlled outpatient trials, and patients who took additional medication or did not experience headache relief before 2 hours were censored at that time.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

This text provides an estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other migraine medication over the 24 hours following the initial dose in pooled Studies 1, 2, 3, and 4. The data shown is from 4 placebo-controlled outpatient clinical trials, with patients not using additional treatments censored at 24 hours. The plot includes patients with and without headache response at 2 hours after the initial dose, and it mentions that remedication was not allowed within 2 hours post-dose.*

FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

This text provides information about the estimated probability of achieving an initial headache response with Rizatriptan Benzoate Orally Disintegrating Tablets within 2 hours in Pooled Studies 5 and 6. It includes details about the Kaplan-Meier plot of the probability over time of obtaining headache response following treatment with Rizatriptan Benzoate tablets or placebo. Data is based on two placebo-controlled outpatient trials (Studies 5 and 6) showing evidence of efficacy.*

FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6. This graph shows the percentage of patients opting for a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets or an alternative migraine medication within the 24 hours following the initial dose across different time points. The data is based on clinical trials and includes patients with varying responses to the initial dose.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

This is a chart showing the observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7. The chart compares the effectiveness of Rizatriptan Benzoate OD Tablets (medication) against a placebo. The data presented is in the form of a line chart with percentage values on the y-axis and hours post Stage 2 dose on the x-axis.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.